The diabetic neuropathic pain market was valued at USD 3.55 Billion in 2025. The market is expected to grow at a CAGR of 7.72% during the forecast period of 2026-2035, with the values likely to reach USD 7.47 Billion by 2035. The market growth is driven by the growing prevalence of diabetes and increasing awareness of neuropathic complications. Advancements in drug formulations, adoption of novel therapeutic targets, and rising focus on personalized pain management approaches will enhance treatment efficacy. Expanding research on neuroprotective therapies and improved healthcare infrastructure are expected to boost market growth during the forecast period.
Base Year
Historical Period
Forecast Period
The increasing number of cases of diabetes is one of the primary drivers of the market for diabetic neuropathic pain.
The rise in regulatory approvals of innovative, patient-centered, non-invasive solutions for the management of diabetic neuropathic pain is a significant market trend.
The growing patient awareness regarding early diagnosis and management of diabetic neuropathy is expected to elevate the market value in the coming years.
Compound Annual Growth Rate
7.72%
Value in USD Billion
2026-2035
*this image is indicative*
Diabetic neuropathic pain occurs as a result of nerve damage in an individual suffering from diabetes. The pain from diabetic neuropathy can range from tingling in the toes or minor discomfort to severe and sharp pain. The damage to the nerves, primarily in the legs and feet, is caused by the high blood sugar levels in the diabetic patient’s body. Around 20 million Americans are reported to suffer from diabetic neuropathic pain. The increasing prevalence of diabetes is a significant factor driving the demand for effective treatments for the condition. The market growth is also supported by the rising introduction of new medications for targeted pain relief such as serotonin and norepinephrine reuptake inhibitors (SNRIs), anticonvulsants, and topical treatments. Additionally, the growing awareness among patients about diabetic neuropathic pain and the rise in drug approvals by regulatory agencies are anticipated to fuel the market growth.
Increasing Prevalence of Diabetes Drives Market Growth
According to the IDF Diabetes Atlas, 1 in 8 adults, or roughly 783 million individuals are projected to be living with diabetes by 2045, due to factors such as rapid urbanization, a growing aging population, sedentary lifestyle patterns, and rising obesity rates. Diabetic neuropathy is considered the most common complication of diabetes mellitus. It affects around 50% of patients with type 1 and type 2 diabetes mellitus. Thus, the rising number of cases of diabetes is one of the primary drivers of the market for diabetic neuropathic pain, propelling the demand for effective treatment options and advanced pain management therapies.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Diabetic Neuropathic Pain Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
The Peripheral Neuropathy Segment Based on Type Holds a Significant Market Share
The market segmentation by type includes peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and others. Peripheral neuropathy ranks as the most common form of diabetic neuropathy. The condition impacts the peripheral nerves (usually legs and feet) and causes symptoms such as burning sensations, tingling, and sharp pain. The high demand for treatments for peripheral neuropathy, including medications such as anticonvulsants, antidepressants, and topical agents, is propelling the growth of the segment.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents one of the largest markets for diabetic neuropathic pain due to the high prevalence of diabetes and the strong presence of major pharmaceutical companies. The growing demand for innovative therapies in the region, including both pharmacological treatments and non-pharmacological options (such as neuromodulation devices) is driving market growth. Moreover, the rising patient awareness regarding early diagnosis and management of diabetic neuropathy is expected to elevate the market value in the country in the coming years.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pharmaceutical industry company Pfizer Inc., headquartered in New York, United States, has a prominent presence in the market and is known for its robust portfolio of medications for pain management and neurological disorders. Pfizer's LYRICA® CR (pregabalin ) extended-release tablets CV is a once-daily FDA-cleared therapy indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NeuroMetrix, Inc., based in Massachusetts, United States, is a spinoff of the Harvard-MIT Division of Health Sciences and Technology. This commercial-stage neurotechnology company is engaged in developing and marketing products that detect, diagnose, and monitor peripheral nerve and spinal cord disorders including diabetic neuropathy.
GSK plc, a British multinational pharmaceutical and biotechnology company, is one of the leading players in the market. The company is known for its extensive research capabilities and a wide range of neurological and pain management products. GSK-3858279, an immunomodulatory monoclonal antibody that targets CCL17, is under clinical development for the treatment of diabetic neuropathic pain.
Johnson & Johnson, headquartered in New Brunswick, New Jersey, plays a significant role in the growth of the market. One of the key products of Johnson & Johnson Innovative Medicine is an oral analgesic NUCYNTA® ER (tapentadol) extended-release tablets for the management of diabetic neuropathy pain.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Lupin, Astellas Pharma, Eli Lilly and Company, Glenmark, Sun Pharmaceuticals Ltd, and Abbott.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share